drugset / Trial / NCT00942188
A Study of LY2189102 in Patients With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
Study to evaluate the safety, tolerability and efficacy of LY2189102 in patients with type 2 diabetes.
Timeline
- Start
- 2009-06
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2189102 | Monoclonal antibody | 0.6 mg | Subcutaneous |
| Subject | LY2189102 | Monoclonal antibody | 18 mg | Subcutaneous |
| Subject | LY2189102 | Monoclonal antibody | 180 mg | Subcutaneous |